Skip to main content
. 2016 Aug 18;12:1249–1260. doi: 10.2147/TCRM.S108094

Figure 7.

Figure 7

Fagan plot analysis to evaluate the clinical utility of methylated CDKN2A for identification of cervical cancer.

Note: With a pretest probability of cervical cancer of 25% (A), 50% (B), and (C) 75% the post-test probability of cervical cancer.

Abbreviations: CDKN2A, cyclin-dependent kinase inhibitor 2A; LR, likelihood ratio.